-
Real World Data inc. raises $30 million
Time of Update: 2021-03-02
By integrating previously fragmented clinical, molecular, therapeutic and therapeutic data, Syapse can help doctors find similar cases and choose the most appropriate personalized precision medicine treatment for patients.
-
Eurofins acquired Transplant Genomics Inc. to expand the diagnostics market
Time of Update: 2021-02-26
The broad market provides an ideal platform for Eurofins to launch TGI's TruGraf blood test, which reliably excludes subclinical renal rejection in patients with kidney transplants with stable kidney function.
-
Gossip about sucralose
Time of Update: 2021-02-15
sucralose swept through the sweetener market, and the company that produces asparta sweets struggled to fight back.
-
Medtron's $235 million acquisition of RF Surgical Systems Inc
Time of Update: 2021-02-13
invasive therapeutics business group's surgical innovation business. The deal is expected to meet Medtron's long-term financial strategy for mergers and acquisitions and will not affect annual earnings. The transaction is awaiting regulatory approval and is expected to close in August 2015. (39 Health Network)
-
agreement for ovarian cancer drugs with ImmunoGen, Inc. of the United States
Time of Update: 2020-11-01
East China Pharmaceuticals has acquired the exclusive clinical development and commercialization interest in Greater China for ImmunoGen U.S. Clinical Phase III research product Mirvetuximab Soravtansine (new antibody-coupled drug ADC for the treatment of ovarian cancer).
-
Br J Nutr: Short-term consumption of high doses of sucralose does not change blood sugar control, insulin resistance, or gut microbiome in healthy people.
Time of Update: 2020-10-12
, eating high doses of sucralose 7 d does not change blood sugar control, insulin resistance, or gut microbiome in healthy individuals.
-
Sedulis' $320 million acquisition of Essen BioScience Inc.
Time of Update: 2020-09-10
with Essen's real-time live cell analysis platform, our lab business has added a key new technology to enhance and accelerate drug development.
-
Canada approves sucralose for nutritional supplements in dry soups.
Time of Update: 2020-08-30
Some of the original reports are as follows: Health Canada's Food Directorate completed a detailed safety assessment of a food source seeking approval for the use of sucralose as a sweetener in the supplement dry soup.
-
Calyxt Inc's gene editing technology interferes with specific genes in organisms.
Time of Update: 2020-08-08
A small, never-profitable company in a suburban Minneapolis lab is trying to beat the world's largest agricultural company to launch the next breakthrough in gene editing, according to foreign media reports. the small company, Calyxt Inc
-
"Pharmaceutical Speed Reader" Sansheng Guoke Co., Inc. IPO ipo of Gilead's $1.25 billion deal.
Time of Update: 2020-08-02
50.1 percent of the latter, with future exercise fees and potential mileage of $1.25 billion. Gilead funded Tizona to develop differentiated first in class oncology immunotherapy. (Pharmaceutical Rubik's Cube) Part 3 Drug Information
-
Plivan completes Clariant mastermaster ingen business acquisition, announces new name: Avient, Inc.
Time of Update: 2020-07-10
PolyOne Corporation (NYSE: POL), a leading global supplier of specialty polymer materials, services and sustainable solutions, has completed its acquisition of Clariant masterbatches business and Clariant Chemical (India). Plevan also announced
-
Plivan completes Clariant mastermaster ingen business acquisition, announces new name: Avient, Inc.
Time of Update: 2020-07-10
July 1, 2020 - PolyOne Corporation (NYSE: POL), a leading global supplier of specialty polymer materials, services and sustainable solutions, has completed its acquisition of the Klein masterbatches business and Clariant Chemical (India
-
Beijing Senoki Pharmaceuticals Co., Inc. variety SNG1153 approved for clinical trials in the U.S.
Time of Update: 2020-06-11
will soon launch clinical trials at the Research and Development Center in Boston, USA, in the hope of further internationalizing the small molecule immunoinnovation drug SNG1153 and making new discoveries in future immuno-combination therapy.
-
FDA grants Promedior Inc. to study antififistosis immunomodulator PRM-151 breakthrough therapy
Time of Update: 2020-06-10
FDA ( granted the company's pre-development anti-fibromy immunomodulator PRM-151 breakthrough therapy for the treatment of iasevere pulmonary fibrosis (IPF).
-
FDA approves New Drug Application for Duchesnay Inc. Osphena (aspemifene)
Time of Update: 2020-06-10
Prior to , Osphena had been approved for the treatment of moderate to severe sexual intercourse difficulties (sexual pain), a symptom of the menopausal VVA.
-
FDA grants Orphazyme Inc. to study drug arimoclomol breakthrough therapy
Time of Update: 2020-06-07
It plays a role in stress cells by stimulating the cell's own heat shock response, increasing the production of HSP70, which in turn reduces the build-up of lipids.
-
Deciphera Inc. submits new drug application to FDA
Time of Update: 2020-06-07
FDA ( for the treatment of patients with advanced gastrointestinal interstitial (GIST) who have been treated with imatinib, sunitinib and regoraib.
-
EpiBone, Inc. approved by FDA to begin first human trials of EB-CMF Phase 1/2
Time of Update: 2020-06-03
This avoids the need to get bones from the patient's body, reduces pain, surgery, and hospital time, while accurately matching defects.
-
JK Plastic Surgery Dean Bai Hui-aid in-depth publication of "Academic Report"
Time of Update: 2020-05-13
Bnt News JK Plastic Surgery President Bai Hui-aid's eye plastic surgery published content has been the attention of Korean plastic surgery specialist.
-
Phoenix Environmental Systems Inc. comes to inspect high-end medical and health programs
Time of Update: 2020-05-12
The team visited the Shoru platform and the new area of the north of the city, and listened to the basic situation of the block and the town planning in the town.
